Moleculin Biotech, Inc.
February 13, 2025 - by Joey Ramson
$MBRX is leading the Prism MarketView Pharmaceuticals index and has gained back its losses so far in 2025 after receiving first country regulatory approval in Europe to begin recruiting for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine
